t(9;11)(p21;q23) KMT2A/MLLT3
2016-03-01 Jeroen Knijnenburg  , Jeroen Knijnenburg   Affiliation1.Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands. [email protected]
2.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Abstract
Review on t(9;11)(p21;q23), with data on clinics, and the genes involved.
Clinics and Pathology
Disease
Phenotype stem cell origin
M5 most often (especially M5a, M4); both found in de novo and therapy related AML with antitopoisomerase II drugs (epipodophyllotoxins, anthracyclins, actinomycin D).
Immunophenotype typically shows positivity for CD11, CD13, CD15 and CD33, but less often shows positivity for CD14, CD34 and lymphoid markers.
Epidemiology
Clinics
Cytology
Prognosis
Cytogenetics
Cytogenetics morphological
Cytogenetics molecular
Additional anomalies
Variants
Genes Involved and Proteins
Result of the Chromosomal Anomaly
Description
Expression localisation
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 41419472 | 2025 | Thrombopoietin increases susceptibility for EVI1 + KMT2A-MLLT3-driven AML expressing stem cell genes linked to poor outcome. | 99 |
| 34830251 | 2021 | Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB). | 86 |
| 36555852 | 2022 | An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene. | 82 |
| 39329074 | 2024 | Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in KMT2A-rearranged acute leukemia. | 75 |
| 39834944 | 2024 | Loss of SMAD1 in acute myeloid leukemia with KMT2A::AFF1 and KMT2A::MLLT3 fusion genes. | 72 |
| 37019972 | 2023 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | 71 |
| 29720585 | 2018 | De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. | 70 |
| 36843114 | 2023 | Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes. | 70 |
| 33375773 | 2022 | Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis. | 69 |
| 39380002 | 2024 | The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency. | 68 |
| 33419897 | 2021 | Therapy-induced Deletion in 11q23 Leading to Fusion of KMT2A With ARHGEF12 and Development of B Lineage Acute Lymphoplastic Leukemia in a Child Treated for Acute Myeloid Leukemia Caused by t(9;11)(p21;q23)/KMT2A-MLLT3. | 66 |
| 35793392 | 2022 | In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies. | 65 |
| 42347168 | 2026 | Comprehensive lincRNA Transcriptome in Acute Myeloid Leukemia: Integrating Known and Newly Identified lincRNAs Across Pediatric and Adult Cohorts. | 65 |
| 32414848 | 2021 | Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia. | 60 |
| 35153769 | 2021 | Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia. | 60 |
| 41545699 | 2026 | CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties. | 59 |
| 39093953 | 2024 | The E3 ubiquitin ligase Herc1 modulates the response to nucleoside analogs in acute myeloid leukemia. | 58 |
| 33803739 | 2021 | Induction of AML Preleukemic Fusion Genes in HSPCs and DNA Damage Response in Preleukemic Fusion Gene Positive Samples. | 58 |
| 42014858 | 2026 | HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia. | 56 |
| 39626355 | 2025 | TIFAB modulates metabolic pathways in KMT2A::MLLT3-induced AML through HNF4A. | 55 |
| 42589252 | 2026 | Effect of the Proteasome Inhibitor, Bortezomib, on Histone Modifications in Human Leukemic Cell Lines. | 53 |
| 35884834 | 2022 | Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group. | 51 |
| 39704147 | 2025 | Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia. | 50 |
| 40316511 | 2025 | Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group. | 50 |
| 33020282 | 2020 | Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A. | 50 |
| 41066431 | 2025 | Detection of leukemia gene fusions on DNA-level through targeted Next-Generation Sequencing. | 47 |
| 41438598 | 2026 | Targeting dysregulated epigenetic and transcription factor networks in KMT2A-rearranged AML using iPSC models. | 47 |
| 41985006 | 2026 | PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells. | 46 |
| 37113989 | 2023 | Whole transcriptome sequencing reveals HOXD11-AGAP3, a novel fusion transcript in the Indian acute leukemia cohort. | 46 |
| 36585787 | 2023 | Discovery of fusion circular RNAs in leukemia with KMT2A::AFF1 rearrangements by the new software CircFusion. | 45 |
| 41959134 | 2026 | Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2Ar and NPM1-m AML. | 45 |
| 39858509 | 2025 | Lipopolymers as the Basis of Non-Viral Delivery of Therapeutic siRNA Nanoparticles in a Leukemia (MOLM-13) Model. | 44 |
| 35326705 | 2022 | CDK6 Degradation Is Counteracted by p16(INK4A) and p18(INK4C) in AML. | 42 |
| 38965370 | 2024 | Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study. | 40 |
| 38226414 | 2024 | Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia. | 39 |
| 36452349 | 2022 | Analytical study of RUNX1-RUNXT1, PML-RARA, CBFB-MYH11, BCR-ABL1(p210) , and KMT2-MLLT3 in Mexican children with acute myeloid leukemia: A multicenter study of the Mexican interinstitutional group for the identification of the causes of childhood leukemia (MIGICCL). | 39 |
| 26648836 | 2015 | Cytogenetic and Molecular Findings in Children with Acute Lymphoblastic Leukemia: Experience of a Single Institution in Argentina. | 38 |
| 38427924 | 2024 | Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). | 37 |
| 41681872 | 2026 | Impact of Fusion Partners and Transplantation Benefit in Intensively Treated KMT2A-Rearranged Acute Myeloid Leukemia. | 36 |
| 38621200 | 2024 | Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia. | 35 |
| 35677155 | 2022 | The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression. | 35 |
| 34134472 | 2022 | RXRA DT448/9PP generates a dominant active variant capable of inducing maturation in acute myeloid leukemia cells. | 32 |
| 42187108 | 2026 | Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA Group. | 31 |
| 31807181 | 2019 | An extra chromosome 9 derived from either a normal chromosome 9 or a derivative chromosome 9 in a patient with acute myeloid leukemia positive for t(9;11)(p21.3;q23.3): A case report. | 30 |
| 41853304 | 2026 | Therapy-related acute myeloid leukemia following successful treatment of high-risk neuroblastoma in a pediatric patient: a case report and insights into late complications. | 29 |
| 35918824 | 2022 | Fusion transcript analysis reveals slower response kinetics than multiparameter flow cytometry in childhood acute myeloid leukaemia. | 27 |
| 34330316 | 2021 | Mature B cell acute lymphoblastic leukaemia with KMT2A-MLLT3 transcripts in children: three case reports and literature reviews. | 26 |
| 40094975 | 2025 | Hemophagocytic Lymphohistiocytosis with Predominant T-Lymphocytes in Young Child: An Unusual Presentation of Evolving Acute Myeloid Leukemia. | 25 |
| 41656387 | 2026 | A novel human acute myeloid leukemia cell line SDEY-AML1 with KMT2A: MLLT3, IKZF1: EVX1 fusions exhibits high tumorigenicity in NSG mice. | 25 |
| 38143534 | 2023 | A single scalp nodule as the first presentation of acute lymphoblastic leukemia (KMT2A::MLLT3) in a healthy-appearing infant: a case report. | 21 |
| 33469688 | 2021 | Umbilical cord blood transplantation can overcome the poor prognosis of KMT2A-MLLT3 acute myeloid leukemia and can lead to good GVHD-free/relapse-free survival. | 20 |
| 33303709 | 2020 | Changing the frequency and spectra of chromosomal aberrations in Korean patients with acute leukemia in a tertiary care hospital. | 19 |
| 35933338 | 2022 | Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements. | 19 |
| 42161656 | 2026 | [Clinical characteristics and prognostic analysis of adult KMT2A-associated acute myeloid leukemia]. | 17 |
| 34120595 | 2021 | Novel combined variants of WT1 and TET2 in a refractory and recurrent AML patient. | 16 |
| 35467057 | 2022 | PAX5 alterations in an infant case of KMT2A-rearranged leukemia with lineage switch. | 15 |
| 42020782 | 2026 | A transgenic zebrafish leukemia model driven by KMT2A::MLLT3 (MLL-AF9). | 15 |
| 30953031 | 2019 | FLT3(N676K) drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis. | 15 |
| 42613434 | 2026 | Modeling KRAS mutations in KMT2A::MLLT3 acute myeloid leukemia promotes leukemic progression and transcriptional rewiring. | 14 |
| 40965326 | 2025 | Balancing benefit and burden: treatment intensification in paediatric KMT2A rearrangements acute myeloid leukaemia. | 12 |
| 38162585 | 2024 | Acute myeloid leukemia cutis with KMT2A::MLLT3 fusion presenting with leonine facies. | 10 |
| 31745420 | 2019 | KMT2A-MLLT3 AML Masquerading as JMML may Disguise Fatal Leukemia. | 8 |
| 36930260 | 2023 | Sustained spontaneous remission in KMT2A-MLLT3 mutated myeloid sarcoma. | 0 |
| 35506873 | 2022 | Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. | 0 |
| 36653696 | 2023 | Comprehensive molecular understanding of pediatric acute myeloid leukemia. | 0 |
| 39633068 | 2025 | HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia. | 0 |
| 39891826 | 2025 | Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities. | 0 |
| 41040298 | 2025 | Dual Targeting of IKKβ and NR4A1 for AML Therapy. | 0 |
| 39672769 | 2025 | Next-generation sequencing RNA fusion panel for the diagnosis of haematological malignancies. | 0 |
| 33871895 | 2021 | A case of KMT2A-MLLT3 fusion-positive mature B-cell acute lymphoblastic leukemia. | 0 |
| 41631723 | 2026 | Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial (JCCG AML-12). | 0 |
| 42862766 | 2026 | Three-Way Chromosomal Translocation Involving KMT2A::MLLT3 in AML: A Case Report and Genomic Characterization. | 0 |
| 29532520 | 2018 | Clinicopathological characteristics of de novo and secondary myeloid sarcoma: A monocentric retrospective study. | 0 |
| 42925915 | 2026 | Comparative analysis of KMT2A fusions in human models of acute myeloid leukemia. | 0 |
| 42533114 | 2026 | PROTAC-mediated targeting of IKKβ and NR4A1 for AML therapy. | 0 |
| 32368831 | 2020 | Impact of immunophenotypic characteristics on genetic subgrouping in childhood acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) study L04-16. | 0 |
| 32175599 | 2020 | Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia. | 0 |
| 28785923 | 2017 | A Case of Acute Myeloid Leukemia with Novel Translocation t(6;11)(p22.2;q23) and Concurrent Insertion ins(11;9)(q23;p21.3p21.3). | 0 |
| 28595195 | 2017 | GAS6 Oncogene and Reverse MLLT3-KMT2A Duplications in an Infant with Acute Myeloid Leukemia and a Novel Complex Hyperdiploid Karyotype: Detailed High-Resolution Molecular Cytogenetic Studies. | 0 |
| 30277115 | 2019 | Panoramic view of common fusion genes in a large cohort of Chinese de novo acute myeloid leukemia patients. | 0 |
| 31205223 | 2019 | Primary Cutaneous Diffuse Large B-Cell Lymphoma With KMT2A-MLLT3: An Infantile Case Study. | 0 |
| 33392975 | 2021 | Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature. | 0 |
| 34894139 | 2022 | Detection of a Cryptic KMT2A/AFDN Gene Fusion [ins(6;11)(q27;q23q23)] in a Pediatric Patient with Newly Diagnosed Acute Myeloid Leukemia. | 0 |
| 33150819 | 2021 | KMT2A-rearranged diffuse large B-cell lymphoma in a child: a case report and molecular characterization. | 0 |
| 36472792 | 2023 | Lineage switch in a pediatric patient with KMT2A-MLLT3 from acute megakaryoblastic leukemia to T cell acute lymphoblastic leukemia at the fourth relapse after allo-HSCT: with literature review. | 0 |
| 33827367 | 2021 | Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis. | 0 |
| 40773175 | 2025 | Atypical cytoplasmic inclusions and erythrophagocytosis in acute myeloid leukemia with KMT2A::MLLT3 and U2AF1 mutation. | 0 |
| 28871137 | 2018 | C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation. | 0 |
| 30701458 | 2019 | Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature. | 0 |
| 32992102 | 2020 | First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia. | 0 |
| 30203571 | 2018 | KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory. | 0 |
| 31701557 | 2019 | Establishment and characterization of a DOT1L inhibitor-sensitive human acute monocytic leukemia cell line YBT-5 with a novel KMT2A-MLLT3 fusion. | 0 |
| 36358022 | 2023 | The adverse impact of ecotropic viral integration site-1 (EVI1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes. | 0 |
| 41918382 | 2026 | [Analysis of ten cases of Acute lymphoblastic leukemia with non-KMT2A::AFF1 transcriptional variant 11q23 rearrangements]. | 0 |
Bibliography
No bibliography items were found for this article.
Summary
Fusion gene

Citation
Jeroen Knijnenburg ; Jeroen Knijnenburg
t(9;11)(p21;q23) KMT2A/MLLT3
Atlas Genet Cytogenet Oncol Haematol. 2016-03-01
Online version: http://atlasgeneticsoncology.org/haematological/1001/t%289%3B11%29%28p21%3Bq23%29
Historical Card
1997-12-01 t(9;11)(p21;q23) KMT2A/MLLT3 by Jean-Loup Huret,Jean-Loup Huret  Affiliation
